Japan Japan’s Opportunity to Establish a Blueprint for the World: Janssen Japan’s Chris Hourigan makes the case for increased investment in, and access to, innovative medicines as a key solution to countering the costs associated with an ageing population. Earlier this year, Emperor Naruhito ascended the Chrysanthemum Throne, and Japan…
Thailand Under Thailand’s Universal Coverage Scheme, Thai citizens at every stage of life are entitled to essential health services and 99% of its population are currently covered. This year, not resting on its laurels, the NHSO’s priorities are the introduction of expanded benefits and subsidies and identifying those who still remain…
Biotech China’s rapidly-growing biotech sector is increasingly hungry for preclinical drug candidates to commercialise in China, and Chinese companies are spending top dollar for cutting-edge technology from the US and UK. Despite mounting US-China tensions in the life sciences, the demand remains strong for cross-border licensing deals, which are raising drug…
Biotech Taiwan has long been a leader in biotechnology research and development. With the government’s emphasis on higher education and research, Taiwan has trained a diverse pool of talent in the scientific and technical fields, which is what is required to drive innovation in multidisciplinary biomedical research. PwC estimated that biotech…
USA Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry. Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the…
Thailand PharmaBoardroom last reported on Thailand in 2015, meeting country managers from across the healthcare and life sciences value chain. Here, we chart some of their career progressions since then. Sticking with Servier Guillaume Drianno Guillaume Drianno was Thailand country manager for French firm Servier between 2013 and 2017. Prior…
China Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high school chemistry teacher, and Zhong, a former factory technician, overtake Robin Li, founder of Chinese search engine giant Baidu, and…
Biotech Taiwan’s biotech sector is growing rapidly and increasingly embracing advanced fields such as precision medicine and AI. However, Johnsee Lee, chairman of the Taiwan Bio Industry Organization warns that the island’s bio industry must become even more collaborative in order to achieve further success and increase its global market share. …
China PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in China, but local players are already releasing their own drugs, sometimes at a third of the price. This represents a…
China More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State Council. These proposals include improving disease and treatment systems, expanding rural healthcare, and reforming hospital management and pricing. Health…
China The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both countries and regulatory reform underway in China, Indian firms are jumping at the chance to bring their competitively-priced drugs to…
China The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the second largest biotech funding hub in the world. Hansoh Pharmaceutical, one of China’s fastest-growing pharma companies, raised a billion…
See our Cookie Privacy Policy Here